Related Experiment Video
Updated: Aug 16, 2025

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
Published on: September 15, 2018
[Identifying possible homozygous familial hypercholesterolemia patients: an Italian experts' opinion]
Claudio Bilato1, Alberto Zambon2, Livia Pisciotta3
1Dipartimento Cardiovascolare, Azienda ULSS 8 Berica, Arzignano (VI).
Insights
Homozygous familial hypercholesterolemia (HoFH) is a rare genetic disorder causing dangerously high LDL cholesterol. Italian experts propose algorithms to help identify potential HoFH patients for early, specialized lipid-lowering therapy.
Area of Science:
- Cardiovascular Medicine
- Genetics
- Metabolic Disorders
Context:
- Homozygous familial hypercholesterolemia (HoFH) is a rare genetic condition.
- Characterized by extremely high low-density lipoprotein cholesterol (LDL-C) levels.
- Leads to premature atherosclerosis and severe cardiovascular events.
Purpose:
- To provide practical guidance for identifying potential HoFH cases.
- To facilitate early diagnosis and prompt initiation of lipid-lowering therapy.
- To address the challenge of HoFH rarity in non-specialized centers.
Summary:
- HoFH results from mutations in genes like LDLR, APOB, PCSK9, and LDLRAP1.
- Untreated HoFH has a very high mortality rate, with fatalities recorded even in early childhood.
- Italian experts developed three algorithms to aid in suspecting and identifying HoFH patients.
- Suspected cases should be referred to specialized centers for optimal management.
Impact:
- Early identification and treatment are crucial to prevent or delay cardiovascular complications.
- The proposed algorithms aim to improve the detection rate of HoFH.
- Facilitates timely referral to specialized centers for effective management of this rare disease.
Abstract:
Homozygous familial hypercholesterolemia (HoFH) is a rare genetic disease characterized by high plasma levels of low-density lipoprotein cholesterol (LDL-C) and massive risk of premature atheromasia and cardiovascular events. HoFH is caused by mutations in several genes, such as LDLR, APOB, PCSK9 and LDLRAP1. If untreated, the average age of death is 18 years old, but fatalities within the first 5 years of age have been recorded. Therefore, early diagnosis and treatment are crucial, in order to prevent and/or delay the cardiovascular complications of LDL-C exposure. Because HoFH is a rare disorder, it is not frequently encountered in daily clinical practice at the primary/secondary unspecialized cardiological centers. Then the availability of practical indications helping to identify HoFH patients or to arise a suspect of HoFH is particularly strategic to promptly start the appropriate lipid-lowering therapy. For such a purpose, a group of Italian experts suggests three useful algorithms to identify cases requiring accurate and specialized clinical evaluation as potential HoFH patients. These cases with suspected HoFH should be addressed to specialized centres for the optimal management of these patients.
Related Concept Videos
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
Atherosclerosis III: Management
Cholesterol: Significance and Regulation
Considering cholesterol and...
Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Lipid-Lowering Drugs: Statins and Miscellaneous Agents

